BMY and PFE Related Headlines
Go Back- Barclays launches U.S. biopharma coverage with four preferred picks
- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
- Bernstein on IRA pricing: $245 really is the floor
- Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- White House: Trump took action on pharma Thursday, sent letters to CEOs
- Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients
- Bristol Myers Squibb and Pfizer launch direct-to-patient Eliquis program
- Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
BMY and PFE Related Press Releases
Go Back- Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
- Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
- Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
